Single-cell transcriptomics has revolutionized our understanding of tumor heterogeneity by enabling the identification of various cell types within solid tumors. The challenge lies in distinguishing malignant cells from non-malignant ones of the same lineage within the tumor microenvironment. This distinction is crucial for understanding tumor growth, invasion, and therapy resistance. Computational methods play a vital role in analyzing single-cell data to identify cancer cells. Techniques such as cell type annotation, identification of cell-of-origin markers, and predicting copy-number alterations are commonly used to differentiate malignant cells from their non-malignant counterparts.
One key aspect in the identification of malignant cells is the use of cell-of-origin markers that define the normal cell type from which the cancer originated. However, tumors often consist of both cancerous and normal cells from the same lineage, making it challenging to solely rely on cell-of-origin markers for classification. Additional features like copy-number alterations, inter-patient tumor heterogeneity, single-nucleotide alterations, and gene fusions provide valuable insights into distinguishing malignant cells. Computational tools such as InferCNV, CopyKAT, and scFusion have been developed to predict copy-number alterations and fusion transcripts in single-cell data, aiding in the identification of cancer cells.
Inter-patient tumor heterogeneity is another critical factor that influences the classification of malignant cells. Differences in gene expression profiles between cancer cells from different patients highlight the unique nature of each tumor. Leveraging patient-specific clusters and measuring cluster mixing can help in distinguishing malignant cells based on their transcriptional profiles. Additionally, the detection of single-nucleotide alterations and gene fusions in scRNA-seq data offers further insights into identifying cancer cells, especially in cancer types where these alterations are more prevalent.
The dysregulation of molecular pathways in cancer cells, such as cell proliferation and immune evasion mechanisms, provides additional criteria for distinguishing malignant cells. Alterations in signaling pathways and immune checkpoint molecules can serve as biomarkers for cancer cell identification. Understanding the metabolic reprogramming of cancer cells, including their preference for specific nutrients and energy sources, can also aid in the classification of malignant cells. By integrating multiple computational approaches and molecular features, biotech operations leaders can effectively identify and characterize cancer cells using single-cell transcriptomics data at scale.
Takeaways:
1. Computational methods play a crucial role in identifying malignant cells in single-cell transcriptomics data by leveraging features such as cell-of-origin markers, copy-number alterations, and gene fusions.
2. Inter-patient tumor heterogeneity provides valuable insights into the unique transcriptional profiles of cancer cells from different patients, aiding in their classification.
3. Molecular pathways, immune checkpoint molecules, and metabolic reprogramming can serve as biomarkers for distinguishing malignant cells, offering additional criteria for cancer cell identification in single-cell data.
4. Integration of diverse computational tools and molecular features enables biotech operations leaders to effectively analyze and characterize cancer cells using single-cell transcriptomics data for large-scale applications.
Tags: transcriptomics, regulatory
Read more on unige.ch